BriaCell is an immuno-oncology focused biotechnology company which develops targeted and safe approaches for the management of cancer, including the first off-the-shelf personalized approach to cancer immunotherapy. The company achieved positive proof-of-concept in a Phase I/IIa clinical trial for its lead product candidate, Bria-IMT™, in patients with advanced breast cancer (ClinicalTrials.gov as NCT03066947). The trial was being conducted along with the co-development of BriaDX™, BriaCell’s companion diagnostic test. Currently, BriaCell is conducting an FDA approved combination study of Bria-IMT™ with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)] in patients with advanced breast cancer (ClinicalTrials.gov as NCT03328026).
BriaCell and Incyte Corporation (NASDAQ: INCY) have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte’s development portfolio with Bria-IMT™ in advanced breast cancer patients.
Capitalizing on insights gained with Bria-IMT™, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized immunotherapy for the treatment for advanced stage Breast Cancer. BriaCell is extending this technology to other forms of cancer.
BriaCell’s small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.BriaCell’s Fact Sheet – June 2019